Zacks Investment Research upgraded shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) from a sell rating to a hold rating in a research report released on Wednesday morning.

According to Zacks, “AMAG reported earnings of $1.57 in the third quarter of 2017 as against the Zacks Consensus Estimate of a loss. However, the company missed the same on revenues. AMAG lowered its total revenue guidance for 2017. Furthermore, the termination of the licensing agreement with Takeda for Feraheme in ex-U.S. territories was a major setback for the company. So far this year, AMAG’s shares have underperformed the industry.  Nevertheless, the company  is working towards label expansion of Feraheme, and potential approval and launch of the Makena subcutaneous auto-injector (SQ) AMAG also remains focused on expanding Makena’s label further in a bid to increase its market share.”

Several other research analysts also recently issued reports on the stock. Jefferies Group LLC reiterated a buy rating and set a $16.00 price target on shares of AMAG Pharmaceuticals in a report on Sunday, November 5th. Morgan Stanley lowered their price target on shares of AMAG Pharmaceuticals from $26.00 to $22.00 and set an overweight rating for the company in a report on Friday, November 3rd. Janney Montgomery Scott reiterated a hold rating on shares of AMAG Pharmaceuticals in a report on Monday, October 23rd. Piper Jaffray Companies began coverage on shares of AMAG Pharmaceuticals in a report on Monday, October 23rd. They set a neutral rating and a $18.00 price target for the company. Finally, Cantor Fitzgerald reiterated a hold rating and set a $21.00 price target on shares of AMAG Pharmaceuticals in a report on Thursday, September 28th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and three have given a buy rating to the stock. The stock presently has a consensus rating of Hold and an average price target of $24.00.

Shares of AMAG Pharmaceuticals (AMAG) traded down $0.15 on Wednesday, reaching $14.05. 763,600 shares of the company’s stock traded hands, compared to its average volume of 1,143,786. AMAG Pharmaceuticals has a 1-year low of $11.93 and a 1-year high of $36.83. The company has a debt-to-equity ratio of 0.94, a current ratio of 1.59 and a quick ratio of 1.48.

ILLEGAL ACTIVITY WARNING: “AMAG Pharmaceuticals, Inc. (AMAG) Raised to “Hold” at Zacks Investment Research” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/11/12/amag-pharmaceuticals-inc-amag-raised-to-hold-at-zacks-investment-research.html.

Several institutional investors have recently modified their holdings of AMAG. BlackRock Inc. grew its stake in shares of AMAG Pharmaceuticals by 67,790.9% in the first quarter. BlackRock Inc. now owns 4,995,412 shares of the specialty pharmaceutical company’s stock worth $112,647,000 after purchasing an additional 4,988,054 shares during the last quarter. State Street Corp grew its stake in shares of AMAG Pharmaceuticals by 75.2% in the first quarter. State Street Corp now owns 2,522,059 shares of the specialty pharmaceutical company’s stock worth $56,876,000 after purchasing an additional 1,082,366 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of AMAG Pharmaceuticals by 152.4% in the first quarter. Dimensional Fund Advisors LP now owns 1,025,673 shares of the specialty pharmaceutical company’s stock worth $23,129,000 after purchasing an additional 619,370 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of AMAG Pharmaceuticals by 162.2% in the first quarter. Goldman Sachs Group Inc. now owns 607,980 shares of the specialty pharmaceutical company’s stock worth $13,710,000 after purchasing an additional 376,139 shares during the last quarter. Finally, Robeco Institutional Asset Management B.V. grew its stake in shares of AMAG Pharmaceuticals by 175.1% in the second quarter. Robeco Institutional Asset Management B.V. now owns 525,989 shares of the specialty pharmaceutical company’s stock worth $9,679,000 after purchasing an additional 334,811 shares during the last quarter.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Get a free copy of the Zacks research report on AMAG Pharmaceuticals (AMAG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Stock Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.